Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
EB-DTNB-NK
- Development stage
- Phase 2
- Lead developer
- Beijing Biotech
- Modality
- CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies, Lymphokine-Activated Killer Cells → Native Immune Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
EB-DTNB-NK is an allogeneic, cord blood-derived natural killer (NK) cell therapy engineered with a dual-target chimeric antigen receptor (CAR) recognizing GD2 and B7-H3 (CD276). Developed by Beijing Biotech, it is intended for the treatment of relapsed or refractory neuroblastoma and ganglioneuroblastoma. The cells are further modified to express interleukin-15 (IL-15) to promote cell survival and expansion, and they incorporate an inducible safety switch to allow for the elimination of the cells in the event of severe toxicity. This dual-targeting approach is designed to enhance tumor recognition and prevent immune escape in solid tumors by addressing antigen heterogeneity.
- Other names
- GD2/B7-H3 CAR-NKdual-target GD2/B7-H3 CAR-NK cells
02
Targets
IL-15R (Interleukin 15 receptor alpha/interleukin 15 complex)B7-H3GD2
Beyond the preview
Go deeper on EB-DTNB-NK.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on EB-DTNB-NK.